MCID: STR015
MIFTS: 36

Stereotypic Movement Disorder malady

Categories: Mental diseases

Aliases & Classifications for Stereotypic Movement Disorder

Aliases & Descriptions for Stereotypic Movement Disorder:

Name: Stereotypic Movement Disorder 12 42 14 69
Stereotyped Repetitive Movements Nos 12
Stereotypy Habit Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2303
ICD10 33 F98.4
ICD9CM 35 307.3
MeSH 42 D019956
SNOMED-CT 64 5507002
UMLS 69 C0038273

Summaries for Stereotypic Movement Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by repeated, rhythmic, purposeless movements or activities such as head banging, nail biting, or body rocking.

MalaCards based summary : Stereotypic Movement Disorder, also known as stereotyped repetitive movements nos, is related to tinea pedis and intracranial aneurysm, and has symptoms including athetosis, clonus and muscular fasciculation. An important gene associated with Stereotypic Movement Disorder is PRL (Prolactin). The drugs Aripiprazole and Antipsychotic Agents have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and eye, and related phenotype is behavior/neurological.

Wikipedia : 71 Stereotypic movement disorder (SMD) is a motor disorder with onset in childhood involving repetitive,... more...

Related Diseases for Stereotypic Movement Disorder

Diseases related to Stereotypic Movement Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 tinea pedis 10.2 ABCB6 SLITRK1
2 intracranial aneurysm 10.2 CLNK SLITRK1
3 fallopian tube disease 10.1 SLITRK1 TAC1
4 trichotillomania 10.1
5 ornithosis 10.1 CCK PRL
6 gaucher's disease 10.1 MECP2 PRL
7 cockayne syndrome type i 10.0 NPY PRL
8 deafness, autosomal recessive 20 10.0 CCK TAC1
9 acute gonococcal cervicitis 10.0 CCK TAC1
10 luxation of globe 10.0 NPY PRL
11 spasmus nutans 10.0
12 primary pigmented nodular adrenocortical disease 10.0 CCK MECP2
13 tuberculous peritonitis 10.0 CCK TAC1
14 simultanagnosia 10.0 CCK TAC1
15 cervical carcinosarcoma 10.0 CCK TAC1
16 hemopericardium 10.0 NPY TAC1
17 chronic erythremia 9.9 NPY TAC1
18 central nervous system lymphoma 9.9 NPY TAC1
19 sweat gland cancer 9.9 CCK TAC1
20 nystagmus 4, congenital, autosomal dominant 9.9 ABCB6 CLNK PRL SLITRK1
21 autism spectrum disorder 9.8 CCK MECP2 TAC1
22 fissured tongue 9.8 CCK NPY
23 epilepsy 9.8
24 mitochondrial disorders 9.8
25 encephalopathy 9.8
26 brain injury 9.8
27 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 9.8 CCK NPY PRL
28 hepatitis d 9.8 CCK NPY PRL
29 cholesteatoma 9.8 CCK NPY
30 mucinous adenocarcinoma 9.8 NPY PRL
31 chagas disease 9.8 CCK NPY
32 infantile hypotonia 9.7 CCK NPY TAC1
33 personality disorder 9.7 CCK MECP2 SLITRK1 TAC1
34 dyspepsia 8.9 ABCB6 CCK CLNK MECP2 NPY PRL

Graphical network of the top 20 diseases related to Stereotypic Movement Disorder:



Diseases related to Stereotypic Movement Disorder

Symptoms & Phenotypes for Stereotypic Movement Disorder

UMLS symptoms related to Stereotypic Movement Disorder:


athetosis, clonus, muscular fasciculation, myoclonus, tremor, recurrent muscle twitches (symptom)

MGI Mouse Phenotypes related to Stereotypic Movement Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.1 CCK MECP2 NPY PRL SLITRK1 TAC1

Drugs & Therapeutics for Stereotypic Movement Disorder

Drugs for Stereotypic Movement Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
2 Antipsychotic Agents Phase 4,Phase 3
3 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
4 Pharmaceutical Solutions Phase 4,Phase 2
5 Psychotropic Drugs Phase 4,Phase 3,Phase 2
6 Tranquilizing Agents Phase 4,Phase 3
7
Sertraline Approved Phase 3,Phase 2 79617-96-2 68617
8
Oxytocin Approved, Vet_approved Phase 2, Phase 3 50-56-6 439302 53477758
9
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
10
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
11
Galantamine Approved Phase 3 357-70-0 9651 908828, 9651
12
Acamprosate Approved, Investigational Phase 2, Phase 3 77337-76-9 71158
13
Ethanol Approved Phase 2, Phase 3 64-17-5 702
14 Antidepressive Agents Phase 3,Phase 2
15 Neurotransmitter Agents Phase 3,Phase 2
16 Neurotransmitter Uptake Inhibitors Phase 3,Phase 2
17
Serotonin Phase 3,Phase 2 50-67-9 5202
18 Serotonin Agents Phase 3,Phase 2
19 Serotonin Uptake Inhibitors Phase 3,Phase 2
20 Oxytocics Phase 2, Phase 3
21 Central Nervous System Stimulants Phase 3
22 Dopamine Agents Phase 3,Phase 2
23 Dopamine Uptake Inhibitors Phase 3
24 Autonomic Agents Phase 3,Phase 2
25 Cholinergic Agents Phase 3,Phase 2
26 Cholinesterase Inhibitors Phase 3,Phase 2
27 Nootropic Agents Phase 3,Phase 2
28 Peripheral Nervous System Agents Phase 3,Phase 2
29
Desipramine Approved Phase 2 50-47-5 2995
30
Citalopram Approved Phase 2 59729-33-8 2771
31
Donepezil Approved Phase 2 120014-06-4 3152
32
Bromocriptine Approved, Investigational Phase 2 25614-03-3 31101
33
Levoleucovorin Approved Phase 2 68538-85-2
34
Melatonin Approved, Nutraceutical, Vet_approved Phase 2 73-31-4 896
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
37 Adrenergic Agents Phase 2
38 Antidepressive Agents, Tricyclic Phase 2
39 Antidepressive Agents, Second-Generation Phase 2
40 Antiparkinson Agents Phase 2
41 Cholinergic Antagonists Phase 2
42 Muscarinic Antagonists Phase 2
43 Parasympatholytics Phase 2
44 Hormone Antagonists Phase 2
45 Hormones Phase 2
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
47 Micronutrients Phase 2
48 Trace Elements Phase 2
49 Vitamins Phase 2
50 Antioxidants Phase 2

Interventional clinical trials:

(show top 50) (show all 58)
id Name Status NCT ID Phase
1 Study to Evaluate the Efficacy and Safety of Aripiprazole Unknown status NCT02069977 Phase 4
2 Repetitive Behavior Disorders in People With Severe Mental Retardation Unknown status NCT00491478 Phase 3
3 Oxytocin in Adolescents With Autism Spectrum Disorders Unknown status NCT02007447 Phase 2, Phase 3
4 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3
5 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
6 Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation Completed NCT00065286 Phase 3
7 Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) Completed NCT00365859 Phase 3
8 A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms Completed NCT00541346 Phase 3
9 Galantamine Versus Placebo in Childhood Autism Completed NCT00252603 Phase 3
10 Study of Acamprosate in Autism Recruiting NCT01813318 Phase 2, Phase 3
11 Reducing Internalized Stigma in People With Serious Mental Illness Completed NCT01259427 Phase 2
12 Ending Self Stigma for PTSD Completed NCT02734212 Phase 1, Phase 2
13 Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Completed NCT00990691 Phase 2
14 Intranasal Oxytocin Treatment for Social Deficits in Children With Autism Completed NCT01624194 Phase 2
15 Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome Completed NCT00114634 Phase 2
16 Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome Completed NCT01253629 Phase 2
17 Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome Completed NCT01357239 Phase 2
18 Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Completed NCT01694667 Phase 2
19 Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1) Completed NCT00086645 Phase 2
20 Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Completed NCT01253317 Phase 1, Phase 2
21 Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders Recruiting NCT02487082 Phase 2
22 Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder Recruiting NCT02909959 Phase 2
23 Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis Suspended NCT00004300 Phase 2
24 A Folinic Acid Intervention for Autism Spectrum Disorders Terminated NCT01602016 Phase 2
25 Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects Unknown status NCT00206791
26 Effects of Hyperbaric Oxygenation Therapy on Adaptive, Aberrant and Stereotyped Behaviors in Children With Autism Unknown status NCT00404846
27 Neuropsychopathological Study of Autism Unknown status NCT01677663
28 The Relationship Between Motor Cortex Oxygenation and Motor Function Recovery in Stroke Patients Unknown status NCT01781689
29 Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study. Completed NCT01037361
30 Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism. Completed NCT00211770
31 "EASY EFFECTIVE SMOKELESS" With NICORETTE® Completed NCT01323491
32 Trial of Vitamin D3 Supplementation in Paediatric Autism Completed NCT02508922
33 An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension Completed NCT01037920
34 Study Evaluating the Nasopharyngeal Carriage in Healthy Children Completed NCT00768833
35 Study of the Preliminary Effect of TEVAW: a Program to Address Intimate Partner Violence in Northern Tanzania Completed NCT02434796
36 LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer Completed NCT01561443
37 Eating Disorder Prevention Programs Completed NCT00042185
38 Effectiveness of a Dissonance-Based Eating Disorder Prevention Program (The Body Project II) Completed NCT00663754
39 Comparative Evaluation of Gabapentine and Occlusal Splint in the Management of Sleep Bruxism Completed NCT01255878
40 Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders Completed NCT02153203
41 Effects of Creatine Supplementation in Rett Syndrome Completed NCT01147575
42 Evaluation of the Positive Prevention PLUS Program Completed NCT02540278
43 Investigating the Cognitive Processes That Underlie Social Knowledge and Behavior Completed NCT00061334
44 Treatment by Therapeutic Body Wraps in Children and Adolescents Suffering From Autism With Severe Injurious Behavior. Completed NCT03164746
45 Genetic and Physical Characteristics of Rett Syndrome Completed NCT00299312
46 The Effect of Resistance to Participant-Supported Reaching on Workspace of the Hand in Severe Chronic Stroke Completed NCT01548781
47 Using Mobile Technology to Reduce Stereotypy Recruiting NCT02124720
48 A Pre and Post Test Intervention Design to Prevent Abortion and Contraceptive-use Stigma Among School Youths in Kenya Recruiting NCT03065842
49 Using Values Affirmation to Reduce the Effects of Perceived Discrimination on Hypertension Disparities Recruiting NCT03028597
50 Improving the Management of Chronic Pain in Primary Care Recruiting NCT02783365

Search NIH Clinical Center for Stereotypic Movement Disorder

Cochrane evidence based reviews: stereotypic movement disorder

Genetic Tests for Stereotypic Movement Disorder

Anatomical Context for Stereotypic Movement Disorder

MalaCards organs/tissues related to Stereotypic Movement Disorder:

39
Testes, Skin, Eye, Brain

Publications for Stereotypic Movement Disorder

Articles related to Stereotypic Movement Disorder:

(show all 14)
id Title Authors Year
1
GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders. ( 25864721 )
2015
2
Stereotypic movement disorder: a case for Procrustes? ( 25039962 )
2014
3
Cheek-biting disorder: another stereotypic movement disorder? ( 21889295 )
2011
4
Stereotypic movement disorder: easily missed. ( 20187883 )
2010
5
Low dimensional temporal organization of spontaneous eye blinks in adults with developmental disabilities and stereotyped movement disorder. ( 19819672 )
2010
6
Trichotillomania (hair pulling disorder), skin picking disorder, and stereotypic movement disorder: toward DSM-V. ( 20533371 )
2010
7
Escitalopram treatment of stereotypic movement disorder in an adolescent with mitochondrial disorder and mental retardation. ( 19519269 )
2009
8
Is trichotillomania a stereotypic movement disorder? An analysis of body-focused repetitive behaviors in people with hair-pulling. ( 19034750 )
2008
9
Trichotillomania, stereotypic movement disorder, and related disorders. ( 17880861 )
2007
10
Opiate sensitivity test in patients with stereotypic movement disorder and trichotillomania. ( 12369265 )
2002
11
Stereotypic movement disorder after acquired brain injury. ( 12097226 )
2002
12
Characteristics of stereotypic movement disorder and self-injurious behavior assessed with the Diagnostic Assessment for the Severely Handicapped (DASH-II). ( 9403928 )
1997
13
Stereotypic movement disorder. ( 9164434 )
1997
14
DSM-IV stereotypic movement disorder: persistence of stereotypies of infancy in intellectually normal adolescents and adults. ( 8617696 )
1996

Variations for Stereotypic Movement Disorder

Expression for Stereotypic Movement Disorder

Search GEO for disease gene expression data for Stereotypic Movement Disorder.

Pathways for Stereotypic Movement Disorder

GO Terms for Stereotypic Movement Disorder

Cellular components related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.02 CCK NPY PRL SLITRK1 TAC1

Biological processes related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.63 CCK MECP2 PRL
2 neuropeptide signaling pathway GO:0007218 9.48 NPY TAC1
3 regulation of blood pressure GO:0008217 9.43 NPY TAC1
4 synapse assembly GO:0007416 9.4 MECP2 SLITRK1
5 positive regulation of synapse assembly GO:0051965 9.37 MECP2 SLITRK1
6 chemical synaptic transmission GO:0007268 9.33 MECP2 NPY TAC1
7 sensory perception of pain GO:0019233 9.32 MECP2 TAC1
8 long-term memory GO:0007616 9.26 MECP2 TAC1
9 behavioral fear response GO:0001662 8.96 CCK MECP2
10 multicellular organismal response to stress GO:0033555 8.62 MECP2 PRL

Molecular functions related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 CCK NPY
2 hormone activity GO:0005179 8.8 CCK NPY PRL

Sources for Stereotypic Movement Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....